Copertina

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	British Journal of Pharmacology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology
di: Lucas Wittenkeller, et al.
Pubblicazione: (2025)

Effects of a pro‐resolving drug in COVID‐19: preclinical studies to a randomized, placebo‐controlled, phase Ib/IIa trial in hospitalized patients
di: Pedro R. J. Almeida, et al.
Pubblicazione: (2024)

Frailty in clinical drug trials: Frailty assessments, subgroup analyses and outcomes
di: Tu N. Nguyen, et al.
Pubblicazione: (2024)

Development of a population pharmacokinetic model for the novel long‐acting injectable antipsychotic risperidone ISM®
di: Christian Laveille, et al.
Pubblicazione: (2024)

The atypical antipsychotics lurasidone and olanzapine exert contrasting effects on the gut microbiome and metabolic function of rats
di: Srinivas Kamath, et al.
Pubblicazione: (2024)

Advancing Alzheimer's disease pharmacotherapy: efficacy of glucocorticoid modulation with dazucorilant (CORT113176) in preclinical mouse models
di: Geoffrey Canet, et al.
Pubblicazione: (2025)

Why and how do we perform physical examination(s) in clinical trials? A use case of drug intervention trials in type 2 diabetes mellitus
di: Julia Kopanz, et al.
Pubblicazione: (2025)

The HIV Pharmacology Data Repository (PDR): Setting a new standard for clinical and preclinical pharmacokinetic data sharing
Pubblicazione: (2024)

External validation of the BAN‐ADHF diuretic‐resistance score in the DAPA‐RESIST clinical trial
di: Dominic M. Alfonso, et al.
Pubblicazione: (2026)

Spotlight commentary: Innovations in clinical trials
di: Nataša Hudej, et al.
Pubblicazione: (2025)

Medication adherence and hospitalizations in older patients with coronary heart disease in Vietnam
di: Tan Van Nguyen, et al.
Pubblicazione: (2025)

The fast‐dissociating D 2 antagonist antipsychotic JNJ‐37822681 is a neuronal Kv7 channel opener: Potential repurposing for epilepsy treatment
di: Lidia Carotenuto, et al.
Pubblicazione: (2025)

Antidepressant and antipsychotic prescribing in patients with type 2 diabetes in Scotland: A time‐trend analysis from 2004 to 2021
di: Charlotte R. L. Greene, et al.
Pubblicazione: (2024)

Why do healthy volunteers participate in clinical trials?
di: Thijs van Iersel, et al.
Pubblicazione: (2026)

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience
di: Juliette A. van den Noort, et al.
Pubblicazione: (2025)

Identifying longitudinal medication adherence patterns of antipsychotic treatments: A real‐world cohort study in Catalonia, Spain
di: Marina Fuente‐Moreno, et al.
Pubblicazione: (2025)

Physiologically based pharmacokinetic model combined with a clinical lactation study to determine doravirine concentrations in human breastmilk
di: Lena van der Wekken‐Pas, et al.
Pubblicazione: (2025)

The first in‐human study to evaluate the antiplatelet properties of the clopidogrel conjugate DT‐678 in acute coronary syndrome patients and healthy volunteers
di: Zhihao Liu, et al.
Pubblicazione: (2024)

Hydroxyl chalcone derivative DK02 as a multi‐target‐directed ligand for Alzheimer's disease: A preclinical study in zebrafish
di: Balasubramanian Haridevamuthu, et al.
Pubblicazione: (2024)

Justifying and reporting the use of stress protocols in pre‐clinical experiments that use animals
di: Andria Michael, et al.
Pubblicazione: (2026)

Complement tunes glutamate release and supports synaptic impairments in an animal model of multiple sclerosis
di: Guendalina Olivero, et al.
Pubblicazione: (2024)

The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview
di: Elise Le Flohic, et al.
Pubblicazione: (2024)

Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approach
di: Jules A. A. C. Heuberger, et al.
Pubblicazione: (2025)

Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy
di: Elisa Kiselev, et al.
Pubblicazione: (2025)

The role of venous capacity in fluid retention with endothelin A antagonism: Mathematical modelling of the RADAR trial
di: Hongtao Yu, et al.
Pubblicazione: (2024)

Characterisation of cotadutide's dual GLP‐1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model
di: Rolien Bosch, et al.
Pubblicazione: (2024)

Contribution of chloride channels to the action potential and contraction in human myometrium during labour
di: Helena C. Parkington, et al.
Pubblicazione: (2025)

Medication adherence during the run‐in phase of clinical trials: A systematic review of methodological and reporting rigour
di: Non Davies, et al.
Pubblicazione: (2025)

Transgender people in clinical trials of drugs and biologics: An analysis of ClinicalTrials.gov from 2007 to 2023
di: Zachary Schonrock, et al.
Pubblicazione: (2024)

Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover‐design trial
di: Alexander Hincker, et al.
Pubblicazione: (2024)

Incorporating transgender and nonbinary participants in phase 1 clinical drug trials: Current knowledge gaps and considerations
di: Lauren E. Walker, et al.
Pubblicazione: (2024)

Infringement of clinical pharmacist's authority
di: Fitriana Mawardi, et al.
Pubblicazione: (2024)

Evaluation of the Medicines and Healthcare products Regulatory Agency's introduction of a risk‐proportionate approach for clinical trials: An analysis of 4617 applications assessed between September 2023 and August 2024
di: Andrea Manfrin, et al.
Pubblicazione: (2025)

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)
di: Serife Kurul, et al.
Pubblicazione: (2025)

Efficiency of computerized clinical decision support systems involving anticoagulants: A flashmob study in Dutch hospital pharmacies
di: Jetske Graafsma, et al.
Pubblicazione: (2024)

Ibuprofen inhibits human sweet taste and glucose detection implicating an additional mechanism of metabolic disease risk reduction
di: Emily C. Hanselman, et al.
Pubblicazione: (2025)

Letter to the editor concerning the article: ‘The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview’
di: Tamás Ágh, et al.
Pubblicazione: (2025)

Development of a novel tyrosine kinase 2 inhibitor ARTS‐011 and its first‐in‐human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects
di: Zhili Jin, et al.
Pubblicazione: (2026)

Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase‐targeted protein degrader BGB‐16673
di: Yue Wu, et al.
Pubblicazione: (2024)

Pharmacokinetics, safety and efficacy study in pregnancy and existing cumulative data/evidence to support clinical use and labelling of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in pregnant women with HIV
Pubblicazione: (2024)